16.49
0.43%
0.07
시간 외 거래:
16.57
0.08
+0.49%
전일 마감가:
$16.42
열려 있는:
$16.4
하루 거래량:
286.07K
Relative Volume:
0.53
시가총액:
$1.04B
수익:
$202.09M
순이익/손실:
$-61.69M
주가수익비율:
-14.09
EPS:
-1.17
순현금흐름:
$-35.64M
1주 성능:
-1.20%
1개월 성능:
+0.92%
6개월 성능:
+23.98%
1년 성능:
+107.94%
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Evolus Inc Stock (EOLS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
2022-06-23 | 개시 | Needham | Buy |
2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
2022-01-20 | 업그레이드 | Truist | Hold → Buy |
2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
2021-04-08 | 재확인 | H.C. Wainwright | Buy |
2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
2020-02-06 | 재개 | Mizuho | Buy |
2019-11-26 | 개시 | SVB Leerink | Outperform |
2019-09-05 | 재개 | Mizuho | Buy |
2019-06-28 | 개시 | Wells Fargo | Market Perform |
2019-06-11 | 개시 | Barclays | Underweight |
2019-03-20 | 개시 | SunTrust | Buy |
2019-02-14 | 개시 | H.C. Wainwright | Buy |
2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Injections For Your Frown Lines Cost Just $49, Thanks To This Membership Club - The Zoe Report
Prescription Hair Loss and Hair Removal Drugs Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Evolus to Participate in Stifel 2024 Healthcare Conference - The Bakersfield Californian
Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Rice Hall James & Associates LLC - MarketBeat
Objective long/short (EOLS) Report - Stock Traders Daily
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Marketscreener.com
Evolus Gets EU Approval for Treatment of Wrinkles - MarketWatch
Evolus gains EU certification for new dermal filler products - Investing.com
Evolus gains EU certification for new dermal filler products By Investing.com - Investing.com UK
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - StockTitan
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - MSN
Evolus (EOLS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers - StockTitan
Semanteon Capital Management LP Purchases Shares of 56,313 Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 25 - GuruFocus.com
Evolus to Report Third Quarter Financial Results on November 6, 2024 - Business Wire
First Week of December 20th Options Trading For Evolus (EOLS) - Nasdaq
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet? - Simply Wall St
When the Price of (EOLS) Talks, People Listen - Stock Traders Daily
Evolus (NASDAQ:EOLS) Shares Down 6.2%Here's Why - MarketBeat
Evolus Inc (EOLS) Stock Price Down 4.81% on Oct 17 - GuruFocus.com
Evolus Inc (EOLS) receives an Overweight rating from Barclays - Knox Daily
SG Americas Securities LLC Makes New $623,000 Investment in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Hits New 1-Year HighTime to Buy? - MarketBeat
Evolus stock soars to 52-week high, hits $17.75 - Investing.com India
Evolus stock soars to 52-week high, hits $17.75 By Investing.com - Investing.com UK
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 14 - GuruFocus.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 12, 2024 - BioSpace
Evolus Inc (EOLS) shows promising results - US Post News
(EOLS) Trading Report - Stock Traders Daily
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years - Yahoo Finance
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Millennium Management LLC - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Invests $1.33 Million in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Q3 2024 Earnings Estimate for Evolus, Inc. Issued By HC Wainwright (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Trading Down 3.4%Here's Why - MarketBeat
Q4 2024 Earnings Forecast for Evolus, Inc. Issued By HC Wainwright (NASDAQ:EOLS) - MarketBeat
Evolus Bus Event - StyleBlueprint
Evolus shares hold Buy rating amid market gains By Investing.com - Investing.com Australia
Evolus shares hold Buy rating amid market gains - Investing.com
A Closer Look at 5 Analyst Recommendations For Evolus - Benzinga
HC Wainwright Reaffirms Buy Rating for Evolus (NASDAQ:EOLS) - MarketBeat
Midday Stock Roundup: NKGen Biotech Plummets 35% - Orange County Business Journal
Stonepine Capital Management LLC Sells 1,016,745 Shares of Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc.'s SWOT analysis: aesthetics stock poised for growth amid challenges - Investing.com UK
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Armistice Capital LLC Acquires Shares of 360,000 Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Defeats Investor Suit Over Botox Trade Secret Dispute - Bloomberg Law
Great Point Partners LLC Has $26.60 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc (EOLS) Shares Up 3.22% on Sep 20 - GuruFocus.com
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):